Ology Bioservices, Inc.

CourtArmed Services Board of Contract Appeals
DecidedMay 20, 2021
DocketASBCA No. 62633
StatusPublished

This text of Ology Bioservices, Inc. (Ology Bioservices, Inc.) is published on Counsel Stack Legal Research, covering Armed Services Board of Contract Appeals primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Ology Bioservices, Inc., (asbca 2021).

Opinion

ARMED SERVICES BOARD OF CONTRACT APPEALS Appeal of - ) ) Ology Bioservices, Inc. ) ASBCA No. 62633 ) Under Contract No. W911QY-13-C-0010 ) et al. )

APPEARANCES FOR THE APPELLANT: Richard B. O’Keeffe Jr., Esq. Gary S. Ward, Esq. Nicole E. Giles, Esq. Wiley Rein LLP Washington, DC

APPEARANCES FOR THE GOVERNMENT: Arthur M. Taylor, Esq. Chief Trial Attorney Patrick B. Grant, Esq. Trial Attorney Defense Contract Management Agency Chantilly, VA

OPINION BY ADMINISTRATIVE JUDGE O’CONNELL ON CROSS-MOTIONS FOR SUMMARY JUDGMENT

This appeal involves a penalty for expressly unallowable costs, namely, executive compensation costs above the threshold established by the Office of Federal Procurement Policy (OFPP). The parties have cross-moved for summary judgment. The Board grants appellant’s motion and denies the government’s cross-motion.

STATEMENT OF FACTS (SOF) FOR PURPOSES OF THE MOTION

The following facts are undisputed for purposes of the motions.

Between 2011 and 2013, appellant, Ology Bioservices, Inc. (Ology) entered into four cost reimbursement contracts with the government, including the contract referenced above. A Defense Contract Management Agency (DCMA) contracting officer (CO) was responsible for negotiating and establishing Ology’s final indirect cost rates for the contracts. (Appellant’s statement of undisputed facts (ASUMF) ¶¶ 3-4; Government statement of genuine issues of material fact (GSMF) ¶¶ 3-4; R4, tab 8). The contracts included FAR 52.242-3, PENALTIES FOR UNALLOWABLE COSTS (MAY 2001), which provides for the assessment of a penalty for costs submitted by the contractor in its proposal that are “expressly unallowable under cost principle in the FAR . . . .” (FAR 52.242-3(d); ASUMF ¶¶ 5, 20; R4, tab 1 at G-000099). The contracts also included FAR 52.242-4, CERTIFICATION OF FINAL INDIRECT COSTS (JAN 1997), which requires a senior official of the contractor to certify, among other things, that the final indirect cost rates do not include any costs that are expressly unallowable under applicable cost principles of the FAR (ASUMF ¶ 5; R4, tab 1 at G-000099; FAR 52.242-4(c)(2)).

The dispute involves compensation to Ology’s chief executive officer (CEO). More specifically, it involves his salary, bonuses and stock option awards valued at $2,730,686. Most of this amount stems from stock option awards valued at $2,253,986 (GSMF ¶¶ 32-41; R4, tab 2 at G-0000160).

The contract referenced above included FAR 52.216-7, ALLOWABLE COST AND PAYMENT (JUN 2011) (R4, tab 1 at G-000102-03). This clause required Ology to submit its final indirect cost rate proposal within six months after the end of its fiscal year, which for Ology was the calendar year. FAR 52.216-7(d)(2). Ology complied with the clause by submitting its FY 2013 proposal on June 30, 2014. After addressing issues identified by the Defense Contract Audit Agency (DCAA), it submitted a revised proposal on December 18, 2014 (ASUMF ¶¶ 6, 22-23; GSMF ¶¶ 6, 22-23).

After a DCAA audit and a lengthy negotiation period between the parties (ASUMF ¶¶ 25-30; GSMF ¶¶ 25-30), the CO issued a final decision on May 13, 2020. Based on an FY 2013 cap for executive compensation of $980,796, the CO determined that Ology had exceeded the cap and included expressly unallowable costs of $1,749,8901 for its CEO in its indirect cost rate proposal. The CO found that $979,938 of this amount was allocated to covered contracts and assessed Ology a penalty in this amount. In addition, she demanded interest that brought the total government claim to $1,109,160 (ASUMF ¶¶ 1, 26, 31; GSMF ¶¶ 1, 26, 31).

DECISION

I. Summary Judgment Standards

Summary judgment is appropriate when there is no genuine issue of material fact and the moving party is entitled to judgment as a matter of law. Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 247-48 (1986). When considering a motion for summary judgment, the Board must determine whether there is a genuine issue for

1 $2,730,686 - $980,796 = $1,749,890 2 trial. Id. at 249. The mere fact that the parties have cross-moved for summary judgment does not require us to grant one of the motions; each must be independently assessed on its own merit. California v. United States, 271 F.3d 1377, 1380 (Fed. Cir. 2001) (citing Ecolab, Inc. v. Envirochem, Inc., 264 F.3d 1358, 1364 (Fed. Cir. 2001)).

II. Relevant Statutes and Regulations Concerning Executive Compensation Costs

As stated above, the contracts included FAR 52.242-3, PENALTIES FOR UNALLOWABLE COSTS (MAY 2011), and FAR 52.242-4, CERTIFICATION OF FINAL INDIRECT COSTS (JAN 1997). These clauses implement statutory and regulatory requirements.

At all times relevant to this dispute, 10 U.S.C. § 2324 provided that:

If the head of the agency determines that a cost submitted by a contractor in its proposal for settlement is expressly unallowable under a cost principle referred to in [the FAR] that defines the allowability of specific selected costs, the head of the agency shall assess a penalty against the contractor. . .

10 U.S.C. § 2324(b)(1); Raytheon Co. v. Sec’y of Def., 940 F.3d 1310, 1312 (Fed. Cir. 2019).

FAR 31.001 defines an “[e]xpressly unallowable cost” as “a particular item or type of cost which, under the express provisions of an applicable law, regulation, or contract, is specifically named and stated to be unallowable.” “The government bears the burden of proving that costs are expressly unallowable and that a penalty assessment was warranted.” Raytheon, 940 F.3d at 1311.

Title 10, Section 2324, identifies specific costs that are unallowable. In 2013, the statute prohibited the reimbursement of employee compensation costs above a benchmark (or cap) established by the Administrator of the OFPP pursuant to 41 U.S.C. § 1127. 10 U.S.C. § 2324(e)(1)(P). Compensation is defined as “the total amount of wages, salary, bonuses, and deferred compensation for the fiscal year, whether paid, earned, or otherwise accruing, as recorded in an employer’s cost accounting records for the fiscal year.” 41 U.S.C. § 1127(a)(3).

OFPP published the cap in the Federal Register. The caps most relevant to this appeal are those for FY 2012 and FY 2013. OFPP published the cap for FY 2012 on December 4, 2013, in the amount of $952,308. OFPP provided that this “amount applies to limit the costs of compensation for contractor employees that are reimbursed

3 by the Government to the contractor for costs incurred on all contracts, after January 1, 2012 and in subsequent contractor FYs, unless and until revised by OFPP.” Determination of Benchmark Compensation Amount for Certain Executives and Employees, 78 Fed. Reg. 72,930 (Dec. 4, 2013) (emphasis added). This was the most recent cap when Ology submitted its revised indirect cost rate proposal on December 18, 2014.

OFPP subsequently published a FY 2013 cap of $980,796, but did not do so until March 15, 2016. The cap applied to costs incurred from January 1 to December 31, 2013.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Ecolab, Inc. v. Envirochem, Inc.
264 F.3d 1358 (Federal Circuit, 2001)
State of California v. United States
271 F.3d 1377 (Federal Circuit, 2001)
Scott Timber Company v. United States
333 F.3d 1358 (Federal Circuit, 2003)
K-Con Building Systems, Inc. v. United States
778 F.3d 1000 (Federal Circuit, 2015)
Lee's Ford Dock, Inc. v. Secretary of the Army
865 F.3d 1361 (Federal Circuit, 2017)
Raytheon Company v. Secretary of Defense
940 F.3d 1310 (Federal Circuit, 2019)

Cite This Page — Counsel Stack

Bluebook (online)
Ology Bioservices, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/ology-bioservices-inc-asbca-2021.